Spellberg Brad J, Ibrahim Ashraf S, Avanesian Valentina, Fu Yue, Myers Carter, Phan Quynh T, Filler Scott G, Yeaman Michael R, Edwards John E
Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles (UCLA) Medical Center, Torrance, Torrance, CA 90502, USA.
J Infect Dis. 2006 Jul 15;194(2):256-60. doi: 10.1086/504691. Epub 2006 Jun 6.
We have shown that vaccination with the recombinant N terminus of Als1p (rAls1p-N) protects mice against disseminated and oropharyngeal candidiasis. We now report that vaccination of mice with a related candidate, rAls3p-N, induces a broader antibody response than rAls1p-N and a similar cell-mediated immune response. The rAls3p-N vaccine was equally as effective as rAls1p-N against disseminated candidiasis but was more effective than rAls1p-N against oropharyngeal or vaginal candidiasis. Antibody titers did not correlate with protection against disseminated candidiasis, but delayed-type hypersensitivity did. The rAls3p-N vaccine is a promising new vaccine candidate for further exploration to prevent systemic and mucosal candidal infections.
我们已经证明，用重组Als1p的N端（rAls1p-N）进行疫苗接种可保护小鼠免受播散性和口咽念珠菌病的侵害。我们现在报告，用相关候选物rAls3p-N对小鼠进行疫苗接种可诱导比rAls1p-N更广泛的抗体反应和类似的细胞介导免疫反应。rAls3p-N疫苗在对抗播散性念珠菌病方面与rAls1p-N同样有效，但在对抗口咽或阴道念珠菌病方面比rAls1p-N更有效。抗体滴度与预防播散性念珠菌病的保护作用无关，但迟发型超敏反应与之相关。rAls3p-N疫苗是一种有前景的新疫苗候选物，有待进一步探索以预防全身性和黏膜念珠菌感染。
